Astellas licenses 4DMT’s AAV vector for ophthalmic targets
Astellas Pharma has entered into an agreement to license 4DMT's R100 vector for a genetic target associated with rare ophthalmic ailments.
Astellas Pharma has entered into an agreement to license 4DMT's R100 vector for a genetic target associated with rare ophthalmic ailments.
What's Your Reaction?
